- Home
- TPST vs HCWB Comparison
TPST vs HCWB Comparison
Compare TPST & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- HCWB
- Stock Information
- Founded
- TPST 2011
- HCWB 2018
- Country
- TPST United States
- HCWB United States
- Employees
- TPST N/A
- HCWB N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- HCWB Biotechnology: Pharmaceutical Preparations
- Sector
- TPST Health Care
- HCWB Health Care
- Exchange
- TPST Nasdaq
- HCWB Nasdaq
- Market Cap
- TPST 45.5M
- HCWB 10.8M
- IPO Year
- TPST N/A
- HCWB 2021
- Fundamental
- Price
- TPST $10.13
- HCWB $4.18
- Analyst Decision
- TPST Hold
- HCWB Strong Buy
- Analyst Count
- TPST 3
- HCWB 1
- Target Price
- TPST $30.00
- HCWB $35.00
- AVG Volume (30 Days)
- TPST 60.6K
- HCWB 5.8M
- Earning Date
- TPST 11-11-2025
- HCWB 11-13-2025
- Dividend Yield
- TPST N/A
- HCWB N/A
- EPS Growth
- TPST N/A
- HCWB N/A
- EPS
- TPST N/A
- HCWB N/A
- Revenue
- TPST N/A
- HCWB $832,841.00
- Revenue This Year
- TPST N/A
- HCWB $178.36
- Revenue Next Year
- TPST N/A
- HCWB N/A
- P/E Ratio
- TPST N/A
- HCWB N/A
- Revenue Growth
- TPST N/A
- HCWB N/A
- 52 Week Low
- TPST $5.35
- HCWB $2.77
- 52 Week High
- TPST $20.67
- HCWB $100.80
- Technical
- Relative Strength Index (RSI)
- TPST 53.41
- HCWB 50.10
- Support Level
- TPST $9.90
- HCWB N/A
- Resistance Level
- TPST $11.02
- HCWB $6.11
- Average True Range (ATR)
- TPST 0.63
- HCWB 0.57
- MACD
- TPST -0.15
- HCWB -0.20
- Stochastic Oscillator
- TPST 33.51
- HCWB 62.76
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.